Thus, the purpose of the current study was first to generate an in vitro model of CML cells resistant to imatinib, and secondly to explore the participation of the drug efflux transporter P-gp in such resistance. Here, PGP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.